CG
ITCI

Carmignac Gestion’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Carmignac Gestion’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,819
Closed -$5.12M – 180
2025
Q1 		$5.12M Buy
+38,819
New +$4.84M 0.08% 74

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Carmignac Gestion's ITCI Position: Q2 2025 in Review

Carmignac Gestion sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 38,819 shares — an estimated $5.12M sold.

Carmignac Gestion first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $5.12M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Carmignac Gestion reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Carmignac Gestion sold 38,819 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.12M.
  • Carmignac Gestion first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Carmignac Gestion's Intra-Cellular Therapies Inc. position peaked at $5.12M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Carmignac Gestion's 13F filing for Q2 2025, filed 13 Aug 2025.